Matinas BioPharma (NYSE American:MTNB) has appointed biotech industry veterans Keith Murphy and Edward Neugeboren to its board of directors (BOD) as independent members, effective today.
Also effective today, Matinas reports that Mathew Wikler, MD, and Natasha Giordano have stepped down from the board.
Mr. Murphy currently serves as a director and executive chairman of Organovo (Nasdaq: ONVO) as well as CEO and chairman of closely held Viscient Bio. Mr. Neugeboren currently serves on the BOD of Grace Therapeutics (NASDAQ: GRCE) and is the chief strategy officer of closely held Cronus Pharma.
“We are thrilled to announce the addition of Keith and Edward to our board,” Jerome D. Jabbour, CEO of Matinas, said. “Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continuing our work to create long-term value for shareholders.”
He added, “We would also like to take this opportunity to thank the departing directors Matthew Wikler and Natasha Giordano for their dedicated service, guidance, and insight during their tenure.”
